SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 1.06

Change

-0.03 (-2.75)%

Market Cap

N/A

Volume

1.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-12 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.51 (-0.65%)

USD 245.07B
AMGN Amgen Inc

-2.46 (-0.73%)

USD 180.14B
SNY Sanofi ADR

-0.42 (-0.73%)

USD 143.70B
GILD Gilead Sciences Inc

-0.11 (-0.13%)

USD 103.10B
BIIB Biogen Inc

-1.37 (-0.69%)

USD 28.50B
GRFS Grifols SA ADR

-0.34 (-3.68%)

USD 7.16B
AMRN Amarin Corporation PLC

N/A

USD 0.24B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.03 (+2.34%)

USD 0.02B
SCLXW Scilex Holding Company

+0.01 (+3.41%)

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.04% 10% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.04% 10% F 17% F
Trailing 12 Months  
Capital Gain -52.68% 20% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.68% 20% F 18% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -33.78% 20% F 8% B-
Dividend Return -33.78% 20% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.10% 30% F 48% F
Risk Adjusted Return -88.68% 20% F 8% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector